Newton Charles W.
SEC Form 4 insider trading activity
Newton Charles W. has filed 5 SEC Form 4 filings (5 transaction rows) across 3 companies, including KROS, CHRS, NVAX, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Aug 20, 2026.
On the most recent filing, Newton Charles W. is listed as Director at Keros Therapeutics, Inc. Inside the rolling window, Newton Charles W. reported no open-market purchases and 2 open-market sales totaling $11K in KROS. The largest disclosed transaction in the window is a sale of 551 KROS shares on Aug 18, 2026, worth $6K.
Companies traded
Other insiders at KROS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$11K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Newton Charles W. made?
Newton Charles W. has filed 5 SEC Form 4 filings (5 transaction rows) across 3 companies, including KROS, CHRS, NVAX since 2026.
Which companies does Newton Charles W. trade?
Newton Charles W. has filed SEC Form 4 disclosures for 3 companies, including KROS, CHRS, NVAX.
When was Newton Charles W.'s most recent SEC Form 4 filing?
Newton Charles W.'s most recent SEC Form 4 filing on Tracefour is dated Aug 20, 2026.
What is Newton Charles W.'s total buy and sell value in the current window?
Inside the rolling retention window, Newton Charles W. bought $0 and sold $11K based on SEC Form 4 filings.
What was Newton Charles W.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 551 KROS shares on 2026-08-18, worth $6K, per SEC Form 4 filings.